Deerfield Management Company, L.P. (Series C) Repligen Corp Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Repligen Corp stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 1,418 shares of RGEN stock, worth $226,695. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,418
Previous 3,362
57.82%
Holding current value
$226,695
Previous $423,000
50.12%
% of portfolio
0.0%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding RGEN
# of Institutions
476Shares Held
54.5MCall Options Held
341KPut Options Held
235K-
Black Rock Inc. New York, NY7.57MShares$1.21 Billion0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.39MShares$1.02 Billion0.11% of portfolio
-
Vanguard Group Inc Valley Forge, PA5.04MShares$806 Million0.01% of portfolio
-
State Street Corp Boston, MA1.62MShares$260 Million0.01% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.42MShares$227 Million1.34% of portfolio
About REPLIGEN CORP
- Ticker RGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Medical Instruments & Supplies
- Shares Outstandng 55,491,200
- Market Cap $8.87B
- Description
- Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....